ABSTRACT: Schistosomes utilize proteinases to accomplish several activities such as tissue penetration, tissue digestion and evasion of host immune responses. Cathepsin L is a cysteine proteinase of the papain superfamily detected in their gut lumen which indicates that this enzyme contributes to the proteolysis of ingested hemoglobin. Due to the roles played in the schistosome biology, proteolytic enzymes are considered potential targets for developing and guiding antischistosomal therapies. In the present work, the cathepsin L1 cDNA coding of Schistosoma mansoni was cloned into the pAE vector that provides high-level expression of heterologous proteins in Escherichia coli. The recombinant protein was expressed as inclusion bodies, purified under denaturing conditions through nickel-charged chromatography and used for experimental animal vaccination. ELISA was performed with the pooled sera. Although this protein was shown to be immunogenic, mice immunized with three doses of recombinant protein plus aluminum hydroxide as adjuvant were not protected against S. mansoni infection.
INTRODUCTION
Schistosomiasis remains a major public health problem in developing countries. It is estimated that 200 million people are infected by it and six hundred million live in risk areas (1) . Despite two decades of widespread chemotherapy with safe and effective drugs, the number of individuals with schistosomiasis remains high (2) . The construction of water resources and agricultural requirements for human development have led to increasing transmission of schistosomiasis (3) . Control of its transmission can be achieved by elimination of intermediary hosts, use of drugs like oxamniquine and praziquantel, besides providing adequate socioeconomic conditions and sanitary education for the population. However, the risk of reintroduction of the disease into a treated area, particularly where there are irrigation projects and population migration, must be taken into account (4, 5) .
Reinfection demands repeated treatment and continued administration of medication, which can favor the emergence of drug-resistant parasites (6) . Moreover, supplying efficient treatment that covers all parts of an endemic area can make chemotherapy an expensive and impractical alternative (7) . Thus, vaccination would be a necessary approach to complement chemotherapy (8) .
Several factors make schistosomiasis vaccine development an advantageous option:
• protective mechanisms have been demonstrated in experimental animals,
• rapid reinfection demands continuing treatment,
• the risk of drug-resistance caused by expanded chemotherapy programs,
• acquired partial immunity reduces the infection intensity as observed in adolescent and older age groups compared to children.
Control based on chemotherapy followed by vaccination would result in a short-term effect with long-term protection (2, 9) . Thus, a definitive vaccine must be elaborated from diverse recombinant antigens and from different parasite stages to improve the possibilities for synergistic action by involving separate defense mechanisms (9) .
Secreted or surface proteins are crucial to maintaining the pathway of parasites through their molecular interaction with host cells. Since these molecules are exposed to the host immune system, they become candidate targets for vaccine development and chemotherapy (10). Miyasato 
Many histochemical and immunolocalizational studies report that cathepsin L (EC 3.4.22.15) is packed into the lysosomal-like vesicles of gastrodermal cells of helminthes and plays an important role in nutrient acquisition (11) . Its strong involvement in hemoglobin digestion indicates that this cysteine proteinase is important to Schistosoma mansoni (12) . Cathepsin L1 was first isolated by Smith et al. (13) whereas its presence was detected in gastrodermal cells lining the gut and in excretory/secretory (ES) products (14) , as later confirmed by immunolocalization studies (15) . Michel et al. (16) constructed an expression plasmid in E. coli to produce recombinant schistosome cathepsin L. The utilization of purified cathepsins L1 and L2 from Fasciola hepatica for vaccination in rats, sheep and cattle has induced protection, ranging from 33 to 80%, in experimental challenge with F. hepatica metacercariae as well as provoked potent anti-embryonation/hatch rate effects (17, 18) . However, there are still no studies on recombinant SmCL1
(cathepsin L1 from Schistosoma mansoni) as a vaccine antigen candidate against S. mansoni infection. Therefore, the general objective of the current work was to verify SmCL1 immunogenicity and feasibility as a vaccine antigen against this worm.
MATERIALS AND METHODS

Bacterial Strains and Plasmids
Escherichia coli DH5α and BL21-SI strains (Invitrogen, USA) were employed in all routine cloning and expression experiments. In the BL21-SI strain, the T7 RNA polymerase expression was controlled by the osmotically inducible promoter proU (19) .
Parasites
Snail intermediate hosts (Biomphalaria glabrata) were infected with S. mansoni BH strain. Cercariae were allowed to shed from infected snails for two hours under a halogen lamp. Cercarial counts and viability were determined through stereomicroscopy (20) .
Cloning Techniques
Total RNA was isolated from S. mansoni worms with Trizol® reagent (Invitrogen, USA). Two micrograms of total RNA was reverse-transcribed by SuperScript II® reverse transcriptase enzyme (Invitrogen, USA) using an oligo(dT) 18 
Expression and Purification of the Recombinant SmCL1 Protein
The pAE SmCL1 plasmid was employed to transform Escherichia coli BL21 SI strain. 
RESULTS
Cloning of SmCL1 cDNA
cDNA was obtained from RNA isolated from adult worms of the Brazilian endemic BH S. mansoni strain. The cDNA sequence of recombinant protein SmCL1 was amplified from two independent RT-PCRs. The amplified segments were cloned into pGEM-T and five independent clones were sequenced. DNA sequence analysis indicated that SmCL1 cDNA sequences were the same found by Smith et al. (13) .
Expression and Purification of Recombinant SmCL1
The expected band of recombinant SmCL1 protein (36.95 kDa) was observed, by SDS-12% PAGE, in bacterial cell lysates from induced cultures (Figure 1, lane 3) . The Cys amino acid residues were indicated by box. The alignment was made by
Program Align X, a component of Vector NTI® suite, version 9.0 (Invitrogen, USA).
DISCUSSION
The results presented herein showed the expression of the recombinant SmCL1 protein in Escherichia coli BL21 SI strain, with high final yield of purified protein. The expressed protein displayed six histidine residues at the carboxy terminus of the recombinant protein, which allowed its purification through affinity chromatography on nickel-charged beads. The recombinant protein was expressed as insoluble inclusion bodies, thus a solubilization step was necessary. In the final purification step, urea concentration in the buffer was maintained at 2 M to avoid protein precipitation, as observed in lower concentrations of urea.
The purified recombinant SmCL1 was not able to hydrolyze hemoglobin (results not shown), which indicates that the purified enzyme was inactive. However, Verity et al. At least three reasons could explain the lack of protection of the recombinant SmCL1 in our conditions. First, there is the possibility that this protein do not provide a complete protection. In this case, it would be necessary to co-administer this antigen with other antigens or adjuvants.
The second factor that could have influenced the protection response of recombinant SmCL1 was the lack of its correct folding, since it was not able to hydrolyze hemoglobin (results not shown). This consequence is distinct from that obtained for the recombinant inactive form of cathepsin D of Schistosoma japonicum, which showed significant protective activity, slightly higher than the recombinant active form produced in insect cells (23) .
In our conditions, protective epitopes may not be presented to the immunized animals. In this regard, it would be interesting to express this antigen in another bacterial expression system, for instance in fusion with maltose binding protein in an attempt to express the protein in a soluble form as used for Schistosoma mansoni tegumental Sm13 antigen (25) or using a protocol able to produce functional and correctly folded F. hepatica cathepsin L in E. coli (18) . On the other hand, expression systems like yeast or insect cells can also be explored in order to obtain functional SmCL1 and to evaluate if properly folded, the recombinant protein is able to improve the level of protection observed in unfolded proteins expressed in E. coli, as described herein. Interestingly, it was observed that even small differences in recombinant proteins may interfere in protection ability. 
